.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, individuals along with metastatic intestinal growths who received biomarker-matched treatments based upon distributing cyst DNA profiling revealed a greater clinical benefit than those getting unrivaled therapy.